NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
INDIUM IN 111 OXYQUINOLINE (indium in-111 oxyquinoline) by GE HealthCare is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 1985.
Drug data last refreshed 10h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Indium In-111 Oxyquinoline is a radioactive diagnostic agent used for nuclear imaging procedures to detect and localize disease. It operates as a radiopharmaceutical that emits gamma radiation, enabling visualization of target tissues and organs. The agent is administered via injection and provides real-time diagnostic information to clinicians.
LOE Approaching
As a decades-old radiopharmaceutical approaching loss of exclusivity, the brand team is likely consolidating support functions and preparing transition strategies rather than investing in growth.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Career Relevance
Working on Indium In-111 Oxyquinoline offers limited career growth due to its legacy status and approaching loss of exclusivity; roles are primarily focused on maintaining market access, managing decline, and supporting transition planning. This position is better suited for professionals seeking stability and expertise in radiopharmaceutical lifecycle management rather than innovation-focused career advancement.
Worked on INDIUM IN 111 OXYQUINOLINE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.